Buscar | La Lingua Nostra

agrega un archivo Health

2026-03-18 10:53:15 -

China Sacroiliitis Treatment Market: How Are JAK Inhibitors Advancing in China's Spondyloarthropathy Market?

JAK inhibitors — tofacitinib and upadacitinib — have received NMPA approval for ankylosing spondylitis, representing the first small-molecule oral disease-modifying options beyond NSAIDs for Chinese AS patients who cannot access or tolerate biologic therapy, with the China Sacroiliitis Treatment Market reflecting the emerging JAK inhibitor market position in China's...

0 Commentarios 0 Acciones 26 Views 0 Vista previa